🟢 Anixa Biosciences is trading 7.31% up in after-hours trading after positive breast cancer vaccine data

Anixa Biosciences is trading 7.31% up in after-hours trading at $2.79 following positive breast cancer vaccine Phase 1 data and encouraging survival observations from its ongoing ovarian cancer CAR-T Phase 1 trial on September 16, 2026.

• Appointed UPenn’s Dr. Carmen Guerra to its Cancer Business Advisory Board, supporting further clinical development.
• The trial update was the clearest catalyst; broader markets were mixed after the Federal Reserve raised rates, making macro sentiment a less likely explanation.